This one-day conference focused on the evidence and experienced-based perspectives by experts in the field with current pharmacotherapies that are used in the treatment of substance use disorders, challenges associated with treatment (including pregnancy and chronic pain), and legal, policy, and administrative issues.
Objectives:
- To understand current pharmacotherapies that are used in the treatment of substance use disorders
- To recognize challenges associated with treatment of substance use disorders in special populations (including pregnancy and chronic pain)
- To understand legal, policy, and administrative issues of relevance to the clinical practice of addiction medicine
Disordered Behavior: The Neurobiology and Underlying Basis of Craving, Relapse and Addiction
Eliot L. Gardner, PhD, Chief of Neuropsychopharmacology Section Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
Objectives:
- To understand the brain circuits and brain mechanisms underlying the "high" produced by addictive drugs, underlying drug craving, and underlying relapses.
- To understand neurobiology mechanism-based anti-addiction medication development.
Bench to Bedside: From the Science to the Practice of Addiction Medicine
Petros Levounis, MD, MA, Chair, Department of Psychiatry, Rutgers New Jersey Medical School; Chief of Service, Department of Psychiatry, University Hospital, Newark, NJ
Objective:
- Describe three effective psychosocial interventions for substance use disorders and their relationship to current neurobiological concepts.
The New Kid on the Block: Incorporating Buprenorphine into a Medical Toxicology Practice
Timothy J. Wiegand, MD, FACMT, Director of Toxicology, University of Rochester Medicine, Rochester, NY; Medical Director, Huther Doyle Chemical Dependency Treatment Program, Rochester, NY
- Review the pharmacology of buprenorphine and the basis by which makes it an useful agent to treat opioid dependence.
- Review the mechanism by which a physician is certified to prescribe buprenorphine and what obligations and subsequent duties that entails.
- Describe the ‘non-certified’ use of buprenorphine including the 3-day “emergency rule”.
- Review the induction, stabilization and maintenance process for use of buprenorphine and describe its appropriate use in outpatient Chemical Dependency treatment and in hospitalized patients.
Chronic Pain, Chronic Opioids Addiction: A Complex Nexus
Edwin A. Salsitz, MD, FASAM, Attending Physician, Beth Israel Medical Center, Division of Chemical Dependency, and Assistant Professor of Medicine, Albert Einstein College of Medicine, New York, NY
Objectives:
- Learn the overlapping neural circuitry for pain and addiction.
- Describe the major risk factors for opioid addiction in patients treated with chronic opioids for chronic pain.
- Review Current treatment paradigms for treatment of pain and addiction.
CASE STUDIES: Clinical Cases: Drug & Alcohol Dependence & Pain
Faculty: JoAn Laes, MD; Petros Levounis, MD, MA, FASAM; Edwin A. Salsitz, MD, FASAM; Daniel L. Sudakin, MD, MPH, FACMT; Timothy J. Wiegand, MD, FACMT
Objectives:
- Describe several different pain management options in patients maintained on buprenorphine or naltrexone for A.) Acute pain and B.) chronic pain.
- List three non-pharmacotherapy pain management options for individuals with substance use disorders.
- Define pseudoaddiction and describe how common a phenomenon this is.
Naltrexone: Not Just for Opioids Anymore
Daniel L. Sudakin, MD, MPH, FACMT, Director of Addiction Medicine, Pathways Northwest (Philomath,OR), Affiliate faculty, Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR
Objectives:
- Understand the pharmacology of naltrexone, including extended release formulations.
- Understand the mechanistic basis and clinical effectiveness for its current FDA-approved uses in alcohol and opioid use disorders.
- Recognize and manage clinical challenges in patient selection, induction and maintenance, and special situations including pain management.
Methadone Maintenance: Putting a Real Face on the Demon
Edwin A. Salsitz, MD, FASAM
Objectives:
- Review the history and evolution of methadone maintenance.
- Understand the evidence base to support the effectiveness of methadone maintenance.
- Demonstrate the severe negative impact of stigma on methadone maintenance treatment.
Special Populations and Addictive Disorders Panel - Case Discussion
Panelists: Daniel L. Sudakin, MD, MPH, FACMT; Timothy J. Wiegand, MD, FACMT; Edwin A. Salsitz, MD, FASAM; JoAn Laes, MD
Objectives:
- Describe the standard of care for treatment of pregnant patient with opioid dependence.
- List three special considerations related to treatment of substance use disorders in adolescent patients
- List three special considerations related to treatment of substance use disorders and addiction in elderly patients
Addiction Medicine Training and Practice
Kevin B. Kunz, MD, MPH, Vice-President, American Board of Addiction Medicine, Medical Director, Hawaii Physicians Program, Clinical Instructor, Department of Psychiatry, School of Medicine, University of Hawaii, Honolulu, HI
The Integration of Medical Toxicology and Addiction Medicine: New Era in Patient Care
Panel: Daniel L. Sudakin, MD, MPH, FACMT; Timothy J. Wiegand, MD, FACMT; JoAn Laes, MD
MENU
